Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 144

1.

Therapeutic exploitation of viral interference.

Kovesdi I, Bakacs T.

Infect Disord Drug Targets. 2019 Apr 5. doi: 10.2174/1871526519666190405140858. [Epub ahead of print]

PMID:
30950360
2.

Post-infection viral superinfection technology could treat HBV and HCV patients with unmet needs.

Bakacs T, Safadi R, Kovesdi I.

Hepatol Med Policy. 2018 Jan 5;3:2. doi: 10.1186/s41124-017-0028-x. eCollection 2018.

3.

Effective multiple oral administration of reverse genetics engineered infectious bursal disease virus in mice in the presence of neutralizing antibodies.

Hornyák Á, Lipinski KS, Bakonyi T, Forgách P, Horváth E, Farsang A, Hedley SJ, Palya V, Bakács T, Kovesdi I.

J Gene Med. 2015 Jun-Jul;17(6-7):116-31. doi: 10.1002/jgm.2830.

PMID:
25929556
4.

[Application of Kohonen Self-Organizing Feature Maps in QSAR of human ADMET and kinase data sets].

Hegymegi-Barakonyi B, Orfi L, Kéri G, Kövesdi I.

Acta Pharm Hung. 2013;83(4):143-8. Hungarian.

PMID:
24575660
5.

Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.

Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, Li XL, Rogers DL, Korokhov N, Kovesdi I, Pereboev AV, Curiel DT, Mathis JM.

PLoS One. 2012;7(10):e46981. doi: 10.1371/journal.pone.0046981. Epub 2012 Oct 8.

6.

Genetic incorporation of human metallothionein into the adenovirus protein IX for non-invasive SPECT imaging.

Mathis JM, Bhatia S, Khandelwal A, Kovesdi I, Lokitz SJ, Odaka Y, Takalkar AM, Terry T, Curiel DT.

PLoS One. 2011 Feb 9;6(2):e16792. doi: 10.1371/journal.pone.0016792.

7.

Recombinant infectious bursal disease virus carrying hepatitis C virus epitopes.

Upadhyay C, Ammayappan A, Patel D, Kovesdi I, Vakharia VN.

J Virol. 2011 Feb;85(3):1408-14. doi: 10.1128/JVI.01391-10. Epub 2010 Nov 24.

8.

Adenoviral producer cells.

Kovesdi I, Hedley SJ.

Viruses. 2010 Aug;2(8):1681-703. doi: 10.3390/v2081681. Epub 2010 Aug 16.

9.

Structure -activity relationships of PDE5 inhibitors.

Eros D, Szántai-Kis C, Kiss R, Kéri G, Hegymegi-Barakonyi B, Kövesdi I, Orfi L.

Curr Med Chem. 2008;15(16):1570-85. Review.

PMID:
18673225
10.

Promoters influence the kinetics of transgene expression following adenovector gene delivery.

Chen P, Tian J, Kovesdi I, Bruder JT.

J Gene Med. 2008 Feb;10(2):123-31.

PMID:
18064718
11.

Rescue and production of vaccine and therapeutic adenovirus vectors expressing inhibitory transgenes.

Gall JG, Lizonova A, EttyReddy D, McVey D, Zuber M, Kovesdi I, Aughtman B, King CR, Brough DE.

Mol Biotechnol. 2007 Mar;35(3):263-73.

PMID:
17652790
12.

Methods for syntheses of N-methyl-DL-aspartic acid derivatives.

Boros M, Kökösi J, Vámos J, Kövesdi I, Noszál B.

Amino Acids. 2007 Nov;33(4):709-17. Epub 2007 Mar 2.

PMID:
17334906
13.

Epitopes expressed in different adenovirus capsid proteins induce different levels of epitope-specific immunity.

Krause A, Joh JH, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG, Worgall S.

J Virol. 2006 Jun;80(11):5523-30.

14.

Targeted and shielded adenovectors for cancer therapy.

Hedley SJ, Chen J, Mountz JD, Li J, Curiel DT, Korokhov N, Kovesdi I.

Cancer Immunol Immunother. 2006 Nov;55(11):1412-9. Epub 2006 Apr 13. Review.

PMID:
16612598
15.

Prediction oriented QSAR modelling of EGFR inhibition.

Szántai-Kis C, Kövesdi I, Eros D, Bánhegyi P, Ullrich A, Kéri G, Orfi L.

Curr Med Chem. 2006;13(3):277-87.

PMID:
16475937
16.

Protection against P. aeruginosa with an adenovirus vector containing an OprF epitope in the capsid.

Worgall S, Krause A, Rivara M, Hee KK, Vintayen EV, Hackett NR, Roelvink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG.

J Clin Invest. 2005 May;115(5):1281-9. Epub 2005 Apr 1.

17.

Marked inhibition of retinal neovascularization in rats following soluble-flt-1 gene transfer.

Rota R, Riccioni T, Zaccarini M, Lamartina S, Gallo AD, Fusco A, Kovesdi I, Balestrazzi E, Abeni DC, Ali RR, Capogrossi MC.

J Gene Med. 2004 Sep;6(9):992-1002.

PMID:
15352072
18.

Muscle stem cells can act as antigen-presenting cells: implication for gene therapy.

Cao B, Bruder J, Kovesdi I, Huard J.

Gene Ther. 2004 Sep;11(17):1321-30.

PMID:
15175641
19.

Adenovirus vectors targeting alphaV integrin or heparan sulfate receptors display different distribution of transgene activity after intramuscular injection.

Cirielli C, Serino F, Straino S, Toietta G, Abeni D, Ventoruzzo G, Orlando G, Mazzanti P, Melillo G, Whickham TJ, Kovesdi I, Biglioli P, Gaetano C, Capogrossi MC.

J Gene Med. 2004 Mar;6(3):309-16.

PMID:
15026992
20.

Delayed angiogenesis in aging rats and therapeutic effect of adenoviral gene transfer of VEGF.

Wang H, Keiser JA, Olszewski B, Rosebury W, Robertson A, Kovesdi I, Gordon D.

Int J Mol Med. 2004 Apr;13(4):581-7.

PMID:
15010860
21.

Increased revascularization efficacy after administration of an adenovirus encoding VEGF(121).

Perrin LA, June JE, Rosebury W, Robertson A, Kovesdi I, Bruder JT, Kessler PD, Keiser JA, Gordon D.

Gene Ther. 2004 Mar;11(6):512-21.

PMID:
14999223
22.

Adenoviral gene transfer of the human inducible nitric oxide synthase gene enhances the radiation response of human colorectal cancer associated with alterations in tumor vascularity.

Wang Z, Cook T, Alber S, Liu K, Kovesdi I, Watkins SK, Vodovotz Y, Billiar TR, Blumberg D.

Cancer Res. 2004 Feb 15;64(4):1386-95.

23.

Comparison of predictive ability of water solubility QSPR models generated by MLR, PLS and ANN methods.

Erös D, Kéri G, Kövesdi I, Szántai-Kis C, Mészáros G, Orfi L.

Mini Rev Med Chem. 2004 Feb;4(2):167-77.

PMID:
14965289
24.

Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.

Worgall S, Busch A, Rivara M, Bonnyay D, Leopold PL, Merritt R, Hackett NR, Rovelink PW, Bruder JT, Wickham TJ, Kovesdi I, Crystal RG.

J Virol. 2004 Mar;78(5):2572-80.

25.

Validation subset selections for extrapolation oriented QSPAR models.

Szántai-Kis C, Kövesdi I, Kéri G, Orfi L.

Mol Divers. 2003;7(1):37-43.

PMID:
14768902
26.

Adenovirus vector library: an approach to the discovery of gene and protein function.

McVey D, Zuber M, Brough DE, Kovesdi I.

J Gen Virol. 2003 Dec;84(Pt 12):3417-22.

PMID:
14645922
27.

In vivo expression and function of recombinant GTPCH I in the rabbit carotid artery.

Hynes SO, Smith LA, Richardson DM, Kovesdi I, O'Brien T, Katusic ZS.

Am J Physiol Heart Circ Physiol. 2004 Feb;286(2):H570-4. Epub 2003 Oct 9.

28.

Lipophilicity of aminopyridazinone regioisomers.

Anwair MA, Károlyházy L, Szabó D, Balogh B, Kövesdi I, Harmat V, Krenyácz J, Gellért A, Takács-Novák K, Mátyus P.

J Agric Food Chem. 2003 Aug 27;51(18):5262-70.

PMID:
12926868
29.

Gene transfer of human guanosine 5'-triphosphate cyclohydrolase I restores vascular tetrahydrobiopterin level and endothelial function in low renin hypertension.

Zheng JS, Yang XQ, Lookingland KJ, Fink GD, Hesslinger C, Kapatos G, Kovesdi I, Chen AF.

Circulation. 2003 Sep 9;108(10):1238-45. Epub 2003 Aug 18.

PMID:
12925450
30.

Local adenoviral-mediated inducible nitric oxide synthase gene transfer inhibits neointimal formation in the porcine coronary stented model.

Wang K, Kessler PD, Zhou Z, Penn MS, Forudi F, Zhou X, Tarakji K, Kibbe M, Kovesdi I, Brough DE, Topol EJ, Lincoff AM.

Mol Ther. 2003 May;7(5 Pt 1):597-603.

31.

In vivo gene transfer of inducible nitric oxide synthase to carotid arteries from hypercholesterolemic rabbits.

Zanetti M, d'Uscio LV, Kovesdi I, Katusic ZS, O'Brien T.

Stroke. 2003 May;34(5):1293-8. Epub 2003 Apr 10.

PMID:
12690222
32.

Regulation of tissue factor expression in smooth muscle cells with nitric oxide.

Kibbe MR, Johnnides C, Gleixner S, Kovesdi I, Lizonova A, Zuckerbraun B, Billiar TR, Tzeng E, Muluk SC.

J Vasc Surg. 2003 Mar;37(3):650-9.

33.

Periocular gene transfer of sFlt-1 suppresses ocular neovascularization and vascular endothelial growth factor-induced breakdown of the blood-retinal barrier.

Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Xiao WH, Duh EJ, Yang HS, Lai H, Kovesdi I, Carrion M, Wei L, Campochiaro PA.

Hum Gene Ther. 2003 Jan 20;14(2):129-41.

PMID:
12614564
34.

Development of an Ad7 cosmid system and generation of an Ad7deltaE1deltaE3HIV(MN) env/rev recombinant virus.

Nan X, Peng B, Hahn TW, Richardson E, Lizonova A, Kovesdi I, Robert-Guroff M.

Gene Ther. 2003 Feb;10(4):326-36.

PMID:
12595891
35.

Inhibitory effect of recombinant iNOS gene expression on vasomotor function of canine basilar artery.

Eguchi D, D'Uscio LV, Wambi C, Weiler D, Kovesdi I, O'Brien T, Katusic ZS.

Am J Physiol Heart Circ Physiol. 2002 Dec;283(6):H2560-6. Epub 2002 Aug 22.

36.

Reliability of logP predictions based on calculated molecular descriptors: a critical review.

Eros D, Kövesdi I, Orfi L, Takács-Novák K, Acsády G, Kéri G.

Curr Med Chem. 2002 Oct;9(20):1819-29. Review.

PMID:
12369880
37.

Adenovirus-mediated E2F-1 gene transfer in nonsmall-cell lung cancer induces cell growth arrest and apoptosis.

Kuhn H, Liebers U, Gessner C, Schumacher A, Witt C, Schauer J, Kovesdi I, Wolff G.

Eur Respir J. 2002 Sep;20(3):703-9.

38.

Modifications in adenoviral coat fiber proteins and transcriptional regulatory sequences enhance transgene expression.

Perlman H, Liu H, Georganas C, Woods JM, Amin MA, Koch AE, Wickham T, Kovesdi I, Mano T, Walsh K, Pope RM.

J Rheumatol. 2002 Aug;29(8):1593-600.

PMID:
12180715
39.
40.

Expression and function of recombinant S1179D endothelial nitric oxide synthase in canine cerebral arteries.

Akiyama M, Eguchi D, Weiler D, O'Brien T, Kovesdi I, Scotland RS, Sessa WC, Katusic ZS.

Stroke. 2002 Apr;33(4):1071-6.

PMID:
11935063
41.

Rapid construction of adenoviral vectors by lambda phage genetics.

McVey D, Zuber M, Ettyreddy D, Brough DE, Kovesdi I.

J Virol. 2002 Apr;76(8):3670-7.

42.

Potentiation of nitric oxide-induced apoptosis in p53-/- vascular smooth muscle cells.

Kibbe MR, Li J, Nie S, Choi BM, Kovesdi I, Lizonova A, Billiar TR, Tzeng E.

Am J Physiol Cell Physiol. 2002 Mar;282(3):C625-34.

44.

Reducing the native tropism of adenovirus vectors requires removal of both CAR and integrin interactions.

Einfeld DA, Schroeder R, Roelvink PW, Lizonova A, King CR, Kovesdi I, Wickham TJ.

J Virol. 2001 Dec;75(23):11284-91.

45.

Inhibition of angiogenesis by adenovirus-mediated sFlt-1 expression in a rat model of corneal neovascularization.

Lai CM, Brankov M, Zaknich T, Lai YK, Shen WY, Constable IJ, Kovesdi I, Rakoczy PE.

Hum Gene Ther. 2001 Jul 1;12(10):1299-310.

PMID:
11440623
46.

Adenovirus-mediated gene transfer of human inducible nitric oxide synthase in porcine vein grafts inhibits intimal hyperplasia.

Kibbe MR, Tzeng E, Gleixner SL, Watkins SC, Kovesdi I, Lizonova A, Makaroun MS, Billiar TR, Rhee RY.

J Vasc Surg. 2001 Jul;34(1):156-65.

47.

Adenovirus type 9 fiber knob binds to the coxsackie B virus-adenovirus receptor (CAR) with lower affinity than fiber knobs of other CAR-binding adenovirus serotypes.

Kirby I, Lord R, Davison E, Wickham TJ, Roelvink PW, Kovesdi I, Sutton BJ, Santis G.

J Virol. 2001 Aug;75(15):7210-4.

48.

Ex vivo adenovirus mediated gene transfection of human conjunctival epithelium.

Shen J, Taylor N, Duncan L, Kovesdi I, Bruder JT, Forrester JV, Dick AD.

Br J Ophthalmol. 2001 Jul;85(7):861-7.

49.

The role of receptors in the maturation-dependent adenoviral transduction of myofibers.

Cao B, Pruchnic R, Ikezawa M, Xiao X, Li J, Wickham TJ, Kovesdi I, Rudert WA, Huard J.

Gene Ther. 2001 Apr;8(8):627-37.

Supplemental Content

Loading ...
Support Center